Novartis AG (NYSE:NVS) saw strong trading volume on Thursday . 3,182,976 shares changed hands during trading, an increase of 163% from the previous session’s volume of 1,210,165 shares.The stock last traded at $78.20 and had previously closed at $78.77.

A number of research analysts have recently commented on the company. Bank of America Corp. reaffirmed a “hold” rating on shares of Novartis AG in a research report on Wednesday, May 18th. Jefferies Group reaffirmed a “buy” rating on shares of Novartis AG in a research report on Friday, May 13th. Citigroup Inc. reissued a “neutral” rating on shares of Novartis AG in a report on Tuesday, May 24th. JPMorgan Chase & Co. reissued a “buy” rating on shares of Novartis AG in a report on Thursday, May 26th. Finally, Zacks Investment Research raised Novartis AG from a “hold” rating to a “buy” rating and set a $92.00 price objective on the stock in a report on Monday, July 11th. Two analysts have rated the stock with a sell rating, ten have issued a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $91.20.

The firm has a market cap of $189.02 billion and a price-to-earnings ratio of 28.34. The firm has a 50-day moving average price of $81.72 and a 200 day moving average price of $77.68.

Novartis AG (NYSE:NVS) last posted its earnings results on Tuesday, July 19th. The company reported $1.23 EPS for the quarter, topping the Zacks’ consensus estimate of $1.18 by $0.05. The business earned $12.47 billion during the quarter, compared to the consensus estimate of $12.33 billion. During the same period in the previous year, the business posted $1.25 EPS. Equities research analysts predict that Novartis AG will post $4.73 earnings per share for the current fiscal year.

Novartis AG is a holding company. The Company specializes in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals, including eye care products. Its portfolio includes medicines, eye care and generic pharmaceuticals. The Company’s segments include Pharmaceuticals, Alcon and Sandoz.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.